*ROB HUTCHISON

A Blood-Brain Barrier Carrier Platform for Delivery of Multiple Classes of Therapeutics for Treating CNS Diseases

Challenge: The blood-brain barrier (BBB) plays an essential role in protecting the brain from blood-borne diseases. However, it blocks otherwise effective medicine from reaching the brain. Most drugs developed for treatment of central nervous system diseases fail because they aren’t optimally designed to cross the BBB. There is a need to identify natural transporters acting as ‘shuttles’ that can facilitate the … Read More

*PATRICK VERMETTE

Development of a New Matrix for Pancreatic Islets Culture and its Validation in a Bioartificial Pancreas

Challenge: Islet transplantation is an efficient therapy to reverse type 1 diabetes. However, the long-term function of the graft is not ensured, and the problem of autoimmunity remains. An interesting alternative consists of a bioartificial pancreas in which islets are encapsulated. However, the islet environment within such a pancreas still needs to be improved to better preserve islet survival and function. … Read More

PAVEL HAMET

Genetic testing to guide therapeutic decision in diabetic patients of various ethnic backgrounds

Challenge: Type 2 diabetes (T2D) is the leading cause of cardiovascular and renal diseases. Although many treatments are available, they only partially reduce the risk of serious complications in diabetic patients. As a first step towards reducing diabetes-related morbidity and mortality, the team has developed a Polygenic Risk Score (PRS) in T2D Caucasian patients that combines with sex, age of … Read More

*EUSTACHE PARAMITHIOTIS

Development of biomarkers for measurement of early stage diabetes disease and for prediction of response to therapy

Competition: FOCUS Program 2009 Funding: $2,360,000 / 3 years  Beginning: September 2014 (COMPLETED PROJECT) Relying on Caprion’s CellCarta proteomics technology to develop panels of protein diabetes biomarkers, this project will improve early diagnosis and monitor disease progression, as well as, evaluate therapeutic response. Overview A unique panel of clinically validated pancreatic ß-cell biomarkers readily detected in blood were discovered which … Read More

PAVEL HAMET

A genetic test to predict diabetic nephropathy in Type 2 diabetes patients

Competition: SynergiQc 2017 Funding: $683,665 / 2 years Beginning: July 2017 Challenge: Occurrence of type 2 diabetes (T2D) is increasing worldwide, and particularly among younger subjects who are more susceptible to renal complications that can lead to renal failure. Such diabetic nephropathy (DN) is present in about 40% of T2D patients. Treatments exist to control renal damage due to T2D … Read More